In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: You can get semaglutide injections (Ozempic® and Wegovy®) and oral semaglutide (Rybelsus®). Injections are usually more ...

As the calendar turns, many people start thinking less about reinvention and more about momentum. A new year is a clean slate, a chance to reset habits and recommit to goals that may have slipped ...

A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...

Last month, the survey firm Statista published Americans’ most common 2026 resolutions. Three of the top five involved losing weight, eating healthy and exercising more. But studies also show a ...

Reaching your goal weight isn’t the finish line. Lose It! members share how they use the app to maintain their progress, support their health, and build healthy habits that last.

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: Medical weight loss is a personalized, medically ...

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

Blockbuster weight-loss shots are undergoing a major makeover. Drugs like Zepbound and Wegovy have already taken the US by storm — with the number of Americans using them to slim down more than ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in patients with type 2 diabetes (T2D) inadequately ...